
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing levetiracetam, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing levetiracetam are listed in tablet, injection, solution and tablet for suspension forms.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Levetiracetam is an antiseizure medicine that compounding pharmacies prepare by prescription.
Levetiracetam is an antiseizure (antiepileptic) drug that is chemically unrelated to other antiseizure drugs. Its exact mechanism is unknown, but it binds synaptic vesicle protein 2A (SV2A), which helps regulate the release of neurotransmitters, and that binding appears to contribute to its antiseizure action. Keppra (levetiracetam tablets and oral solution) is FDA-approved for partial-onset seizures in patients 1 month and older, and as add-on therapy for myoclonic seizures in juvenile myoclonic epilepsy (age 12 and older) and for primary generalized tonic-clonic seizures in idiopathic generalized epilepsy (age 6 and older). Keppra injection, Keppra XR extended-release tablets and many generics are also manufactured. A prescriber might order levetiracetam compounded in a strength, flavor or vehicle that is not manufactured, or without certain excipients. Compounded preparations are not FDA-approved and require a prescription.
Keppra has no boxed warning. It can cause behavior changes such as aggression, irritability, anxiety and depression, and less often psychotic symptoms; like other antiseizure drugs, it raises the risk of suicidal thoughts or behavior. Sleepiness, fatigue and poor coordination can affect driving. Serious reactions include anaphylaxis and angioedema, Stevens-Johnson syndrome and toxic epidermal necrolysis, DRESS and blood count changes. Do not use it if you are allergic to it, and do not stop it suddenly. It has few drug interactions, but kidney impairment requires dose adjustment. In children under 4, diastolic blood pressure can rise. The label reports no drug-associated increase in major birth defects, and blood levels can fall during pregnancy. LactMed notes it can occasionally sedate the breastfed infant and is not necessarily a reason to stop breastfeeding. Talk to your prescriber or pharmacist about mood changes, rash or other side effects.
Levetiracetam binds SV2A, a synaptic vesicle protein involved in exocytosis; among analogs, SV2A affinity correlated with antiseizure potency in animal models. Per the Keppra label, oral bioavailability is 100%, peak concentrations occur in about an hour, tablets and oral solution are bioequivalent, kinetics are linear, and protein binding is under 10%. Metabolism is by enzymatic hydrolysis of the acetamide group without CYP involvement; adult half-life is about 7 hours, longer in older adults, and 66% of a dose is excreted unchanged in urine. Clearance tracks creatinine clearance, so renal dose adjustment and supplemental doses after dialysis are recommended. Labeled indications: partial-onset seizures from 1 month of age; adjunctive therapy for myoclonic seizures in juvenile myoclonic epilepsy and for primary generalized tonic-clonic seizures. StatPearls lists off-label use in status epilepticus, seizure prophylaxis after subarachnoid hemorrhage, traumatic brain injury and supratentorial neurosurgery, and seizures in palliative care; these are not FDA-approved indications. Check baseline creatinine; monitor mood, suicidality and psychosis, and blood pressure in children under 4. Routine drug level monitoring is not recommended but may help in critically ill, pregnant or elderly patients. Withdraw gradually. Dosing is per prescriber. Levetiracetam is not a controlled substance.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally